# Levetiracetam for Persons at Risk for Alzheimer's Disease

> **NCT07477431** · PHASE2 · RECRUITING · sponsor: **Sunnybrook Health Sciences Centre** · enrollment: 40 (estimated)

## Conditions studied

- Hippocampal Hyperactivation
- Prodromal Alzheimer Disease

## Interventions

- **DRUG:** Levetiracetam (LEV)
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07477431
- **Lead sponsor:** Sunnybrook Health Sciences Centre
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-23
- **Primary completion:** 2027-01
- **Final completion:** 2027-02
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-03-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07477431

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07477431, "Levetiracetam for Persons at Risk for Alzheimer's Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07477431. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*